TPO and non-small cell lung carcinoma: In a retrospective study of NSCLC patients treated with PD-1 inhibitors, pre-existing ANA, rheumatoid factor, anti-thyroglobulin and anti-thyroid peroxidase antibody positivity correlated with the development of irAEs, but also with clinical benefit from ICIs (110).